Catalent, Inc. (NYSE:CTLT) Receives $58.08 Average Price Target from Analysts

Catalent, Inc. (NYSE:CTLT - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $58.08.

CTLT has been the topic of several recent research reports. Royal Bank of Canada restated a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. StockNews.com began coverage on shares of Catalent in a research note on Wednesday. They set a "sell" rating on the stock. William Blair reissued a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a research report on Friday, June 28th.

Catalent Price Performance

CTLT stock traded down $0.05 on Wednesday, reaching $60.30. The company had a trading volume of 2,431,479 shares, compared to its average volume of 2,105,335. The company's fifty day moving average is $59.39 and its 200 day moving average is $57.17. The company has a market cap of $10.91 billion, a P/E ratio of -9.89, a PEG ratio of 1.88 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52. Catalent has a 1 year low of $31.80 and a 1 year high of $61.20.

Insider Buying and Selling

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company's stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,409 shares of company stock valued at $782,923. Insiders own 0.31% of the company's stock.

Institutional Investors Weigh In On Catalent

Large investors have recently made changes to their positions in the business. Principal Securities Inc. acquired a new position in shares of Catalent in the 4th quarter valued at approximately $56,000. Jump Financial LLC bought a new position in shares of Catalent in the fourth quarter worth $348,000. Dimensional Fund Advisors LP grew its position in Catalent by 29.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company's stock valued at $73,655,000 after buying an additional 376,931 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in shares of Catalent by 78.9% in the fourth quarter. Panagora Asset Management Inc. now owns 21,766 shares of the company's stock valued at $978,000 after acquiring an additional 9,600 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Catalent during the 4th quarter valued at $116,021,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.